| TOVX 0.41 59.41% | FCHL 0.225 -37.22% | CTNT 0.0548 -42.50% | CMND 1.14 58.42% | BYND 1.16 41.02% | ENVB 3.65 100.55% | WLDS 1.3 -13.91% | TZA 5 -1.57% | LZMH 0.155 -10.71% | NVDA 202.06 0.19% | PLUG 3.22 15.83% | BITO 10.46 -1.60% | TSLL 13.29 -4.39% | INTC 65.7 -4.09% | ONDS 10.73 7.30% | NOK 10.61 2.91% | SOXS 18.63 -1.27% | BMNG 1.55 -3.13% | HIMS 31.01 7.60% | TQQQ 58.08 -0.87% | TSLA 392.5 -2.03% | NFLX 94.83 -2.55% | AAL 12.24 -4.23% | FRMI 5.4 -17.56% | SLNH 1.4 23.89% | BB 5.5 13.17% | NVD 5.59 -0.53% | QXO 24.22 -3.12% | SOFI 19.5 0.36% | SPDN 9.14 0.11% | IONQ 48.32 4.84% | SOXL 95.94 1.33% | SNAP 6 -0.50% | ATAI 4.9 21.59% | GRAB 4.21 0.00% | SQQQ 56.91 0.92% | POET 8.59 18.32% | SIDU 4.34 -18.88% | USAR 22.58 13.18% | MARA 11.63 0.26% | SPY 708.72 -0.20% | PBM 11.3 48.68% | DRIP 5.16 -1.71% | CMPS 9.46 42.04% | ASTS 81 -5.30% | MRVL 147.84 5.83% | BTG 4.94 -1.20% | SRXH 0.1198 -5.67% | ZSPC 1.54 2,400.00% | QBTS 21.655 -0.16%

BIO-key International, Inc. (NASDAQ:BKYI) Reports Q1 2026 Earnings: Key Financial Insights

BIO-key International, Inc. (NASDAQ:BKYI) is a prominent player in the Identity and Access Management sector, specializing in biometric authentication technologies. Despite its leadership position, the company reported an earnings per share (EPS) of -$0.19 on March 31, 2026, which was below the estimated EPS of -$0.07. This indicates a larger-than-expected loss per share for the quarter.

The company's revenue for the quarter was approximately $1.24 million, falling short of the estimated $2.2 million. However, BIO-key's financial results for the full year ending December 31, 2025, showed a revenue of $6.1 million. This suggests that while the quarterly performance was underwhelming, the company had a relatively stronger year overall.

BIO-key's cash position improved significantly, ending 2025 with $2.7 million compared to $400,000 in 2024. This improvement is crucial as it supports the company's expectations for strong growth in 2026. The preliminary results for the first quarter of 2026 show a revenue of $2.2 million, marking a 37% increase compared to the first quarter of 2025.

CEO Mike DePasquale emphasized the strategic transition to selling exclusively BIO-key branded solutions, which positions the company for continued success. Despite the quarterly net loss of about $1.72 million, the company remains optimistic about its future prospects. An investor call is scheduled to discuss these results further, providing stakeholders an opportunity to engage with the company's leadership.

Published on: March 31, 2026